Skip to navigation menu Skip to content
Informational Alert


Blood Cancers

Our team is developing new fusion proteins to improve antitumor T cell function against acute myeloid leukemia (AML).

Solid Tumors

Our new generation of fusion proteins enhance therapeutic efficacy by stimulating endogenous anticancer immunity within the solid tumor microenvironment.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies